BioCentury
ARTICLE | Product Development

GW’s next act

How GW Pharmaceuticals plans to follow up its successful launch of Epidiolex

March 27, 2019 12:44 PM UTC

As Epidiolex’s launch continues to ramp up, GW Pharmaceuticals’ next act will be to take the plunge with its cannabinoid platform into larger, more complex neurobehavioral indications, and even cancer.

Not surprisingly, the rise of GW Pharmaceuticals plc has followed that of Epidiolex cannabidiol, its first wholly owned commercial product. After 12 years on the London Stock Exchange, GW listed on NASDAQ in 2013, since when it has raised over $1.4 billion (see Figure: “GW Fundraising”). ...

BCIQ Company Profiles

GW Pharmaceuticals plc